Oral contraceptives and thromboembolic disease.

Oral contraceptives and thromboembolic disease.

Epidemiological and public health aspects of oral contraceptives and thromboembolic disease'

The possibility that the use of oral contraceptives might increase the risk of thromboembolic disease was first raised by a case report in the Lancet in 1961 (Jordan, 1961). The patient concerned was a 40-year-old nurse who had been given Enavid for the control of endometriosis. After some weeks, the treatment had to be discontinued because of severe vomiting. Ten days later, that is, one week ...

Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report.

The results of a previous study of the use of oral contraceptives by married women discharged from hospital with a diagnosis of thromboembolic disease in the years 1964-6 were reported by us last year. The present paper adds results relating to patients discharged during 1967 and a few data, that could not be sought previously, for patients discharged with cerebral or coronary thrombosis from t...

Oral contraceptives after liver disease.

Administration of oral contraceptives to 10 women was started two weeks after the normalization of the serum enzyme activities in the convalescent period of viral hepatitis, and to five women eight weeks after an operation of obstructive jaundice. Routine liver function tests were performed at intervals of two weeks for two to three months. The liver function tests stayed within normal limits d...

The progestogen content of combined oral contraceptives and venous thromboembolic risk.

In the linked study (doi:10.1136/bmj.d6423), Lidegaard and colleagues assess the effect of different types of combined oral contraceptive, according to progestogen type and oestrogen dose, on the risk of venous thromboembolism. Over the past four decades, more than 25 epidemiological studies have examined the risk of venous thromboembolism in current users of combined oral contraceptives.All bu...